Sotagliflozin and Chronic Kidney Disease

A recent phase 3 clinical trial on the diabetes drug sotagliflozin, an SGLT2 inhibitor, found it had favorable results for people living with severe renal impairment / chronic kidney disease.  Read more

How Do Metformin and Exercise Affect Glucose?

People who have prediabetes or type 2 diabetes are usually urged to make lifestyle modifications, including diet, exercise, and weight control as the first form of treatment; metformin is typically the first drug prescribed when lifestyle interventions are insufficient. A recent study examined how the interface of physical activity and metformin affects post-meal glucose in […]

Drug Combo Could Help Patients Who No Longer Respond to Metformin

Metformin is the first-line drug treatment for type 2 diabetes, but in some patients, the drug’s effectiveness can decline over time. A clinical trial has found that a combination of two newer diabetes drugs, exenatide and dapagliflozin, is effective in patients whose blood glucose levels did not respond to metformin. Read more

Can Semaglutide Add Years to Your Life?

The diabetes drugs known as the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class have demonstrated clear benefit for cardiovascular disease associated with diabetes. Researchers wanted to take a closer look at one GLP-1 RA medication, semaglutide, and determine how many years can be added to a patient’s life with this drug’s addition. Read more

Can DPP-4 Inhibitors Increase Pneumonia Risk?

Patients with diabetes have a higher risk for developing pneumonia, including viral pneumonia. Since the DPP-4 protein plays a role in infection for some coronaviruses, researchers wanted to study whether using DPP-4 inhibitor diabetes drugs could increase risk for pneumonia. Read more

Which Diabetes Drug Class is Better for the Heart?

Uncontrolled or poorly controlled type 2 diabetes is linked to many serious consequences, including death, heart failure, stroke, and myocardial infarction. A recent study compared the use of two antidiabetic medications, SGLT-2 inhibitors (such as Invokana and Jardiance) and GLP-1 receptor agonists (such as Bydureon and Farxiga), to see if one offered better cardiovascular protection. […]

Drugs Used to Treat HIV, Hepatitis May Also Prevent Type 2

A class of drugs called Nucleoside reverse-transcriptase inhibitors (NRTIs), which has long used to treat HIV and hepatitis B viral infections, appears to prevent the development of type 2 diabetes in a substantial number of patients who take these drugs, according to a new data analysis. Read more

Dulaglutide Can Help Protect the Heart

Cardiovascular issues in people with type 2 diabetes are approximately twice as common as in individuals without type 2. The results of a large trial, REWIND, suggest that dulaglutide (also called Trulicity) has cardioprotective properties.  Read more

Mixed Effects of Combining 2 Drugs, Canagliflozin & Liraglutide

Researchers examining the effects of combining the diabetes drugs canagliflozin, an SGLT2i, plus liraglutide, a GLP-1 RA, found that the combo was not much more effective than for lowering HBA1c than liraglutide alone, but the combo did have some weight loss benefits. Read more

How Safe is Dapagliflozin in the Elderly?

The SGLT-2 inhibitors are a relatively new treatment for type 2 diabetes, and the authors of this study felt their use had not yet been adequately studied in the elderly. They examined the effect of one SGLT-2 inhibitor, dapagliflozin (brand name Farxiga) to assess its effects on blood glucose control and kidney health in senior […]

Add an SGLT-2 Sooner Rather Than Later

For most people diagnosed with type 2 diabetes, the first treatments to be prescribed (aside from lifestyle changes like diet and exercise) are metformin or sulfonylureas. If these do not achieve the desired result, doctors may add additional medications. New research says that there is reason to add the SGLT-2 inhibitor early, as the second […]

Sitagliptin Shows Benefit in Diabetes Patients with COVID-19

The type 2 diabetes drug sitagliptin improves survival in patients with diabetes who have been hospitalized with COVID-19, according to Italian researchers. Patients who were given sitagliptin in addition to insulin had a mortality rate of 18 percent, versus 37 percent in similar patients who received insulin alone. Read more

Diabetes Drug Jardiance Shows Heart Failure Benefits

Jardiance (empagliflozin) has been studied for its use in people with heart failure. A study has found it shows effectiveness in patients with reduced ejection fraction (HFrEF). In heart failure with reduced ejection fraction, the heart muscle does not contract efficiently, and a smaller percentage of blood is pumped out of the heart than usual. […]

Newer Type 2 Drugs Increase Out-of-Pocket Costs for Medicare Patients

Recent diabetes guidelines have suggested giving type 2 diabetes patients newer glucose-lowering drugs like SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors, earlier in preference to older drugs like metformin and the sulfonylureas, due to their many benefits. However, for Medicare recipients, the out-of-pocket costs for these drugs are much higher. Read more

SGLT2 Inhibitors May Delay Kidney Disease

Drugs from the SGLT2 inhibitor class of diabetes medications have shown benefit in slowing progression of diabetic kidney disease, with a reduced risk of acute kidney injury (AKI) noted in research trials. People at high risk of AKIs who may be considering SGLT2 treatment should discuss the risks and benefits with their doctors. Read more

FDA Approves New Trulicity Dosages

The FDA has approved 2 additional doses of Eli Lilly’s Trulicity (dulaglutide) for treating type 2 diabetes. The approval of the new 3.0 mg and 4.5 mg doses of dulaglutide was based on clinical trial results showing benefits for A1C levels and weight loss. Read more

Metformin Helps Reduce Presurgical Stress

Surgical procedures cause both physical and mental stress on patients, and higher stress level is associated with an increased risk of complications and death. Researchers examined the effectiveness of metformin use before surgeries to reduce the risk of complications in patients with type 2 diabetes. Read more

Can Diabetes Drugs Fight COVID-19?

Multiple diabetes drugs are undergoing trials to see if they have a role to play in the fight against the novel coronavirus COVID-19. It’s already known that people with diabetes are at higher risk of serious complications from COVID-19; one reason may be that COVID-19 attacks the same bodily systems damaged by type 2 diabetes […]

Assessing the Heart Benefits of Ertugliflozin

The results from a major trial examining whether the diabetes drug ertugliflozin (brand name STEGLATRO), the VERTIS-CV trial, suggest that ertugliflozin is not superior to placebo in reducing major adverse cardiovascular events (MACE) but may reduce the rate of hospitalization for heart failure.  Read more

FDA Removes Amputation Warning for Invokana

Based on recent review of studies showing that the diabetes drug canagliflozin (Invokana) has many benefits for heart and kidney disease, and that the risk of amputation, while still increased with canagliflozin, is lower than previously described, the FDA has concluded that the boxed warning for increased amputation risk should be removed.  It is still important […]